67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
54 citations
,
December 2004 in “PubMed” Cyclosporin A vesicles effectively regrow hair and reduce inflammation in alopecia areata.
37 citations
,
September 2018 in “The Journal of Clinical Endocrinology and Metabolism” Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
October 2020 in “The American journal of gastroenterology” Para-aminobenzoic acid in hair supplements can cause autoimmune hepatitis.
August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
May 1963 in “American journal of obstetrics and gynecology” Injecting 2 ml of TEEV every 4 weeks is better because it has the same benefits but fewer side effects.
October 2024 in “Zagazig University Medical Journal” Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.